Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price indicates a potential upside of 295.60% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

Shares of NASDAQ OMER opened at $9.10 on Friday. The firm has a 50-day simple moving average of $8.70 and a 200-day simple moving average of $7.34. The stock has a market capitalization of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Omeros by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,110 shares during the last quarter. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Omeros by 2.0% during the fourth quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares during the last quarter. Finally, Cerity Partners LLC increased its position in shares of Omeros by 9.9% during the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 2,600 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.